GSK BHR Study (Sont)

Summary

GSK BHR Study (Sont) is a clinical trial^[1].

Key Facts

• GSK BHR Study (Sont) is located in Puerto Rico^[2].
• GSK BHR Study (Sont) is in the country of Brazil^[3].
• GSK BHR Study (Sont) is in the country of Latvia^[4].
• GSK BHR Study (Sont) is in the country of United States^[5].
• GSK BHR Study (Sont)'s instance of is recorded as clinical trial^[6].
• GSK BHR Study (Sont)'s start time is recorded as +2003-02-28T00:00:00Z^[7].
• GSK BHR Study (Sont)'s end time is recorded as +2004-10-31T00:00:00Z^[8].
• GSK BHR Study (Sont)'s sponsor is recorded as GSK^[9].
• GSK BHR Study (Sont)'s main subject is recorded as asthma^[10].
• GSK BHR Study (Sont)'s number of participants is recorded as {'unit': '1', 'amount': '+464'}^[11].
• GSK BHR Study (Sont)'s title is recorded as A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo BID if Asymptomatic)^[12].
• GSK BHR Study (Sont)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+12'}^[13].
• GSK BHR Study (Sont)'s ClinicalTrials.gov ID is recorded as NCT00920543^[14].
• GSK BHR Study (Sont)'s research intervention is recorded as salmeterol xinafoate^[15].
• GSK BHR Study (Sont)'s clinical trial phase is recorded as phase IV clinical trial^[16].
• GSK BHR Study (Sont)'s research site is recorded as GSK^[17].
• GSK BHR Study (Sont)'s study type is recorded as interventional study^[18].